GPC2 antibody–drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies

BACKGROUND: Antibody–drug conjugates (ADCs) that deliver cytotoxic drugs to tumor cells have emerged as an effective and safe anticancer therapy. ADCs may induce immunogenic cell death (ICD) to promote additional endogenous antitumor immune responses. Here, we characterized the immunomodulatory prop...

Descripción completa

Detalles Bibliográficos
Autores principales: Pascual-Pasto, Guillem, McIntyre, Brendan, Shraim, Rawan, Buongervino, Samantha N, Erbe, Amy K, Zhelev, Doncho V, Sadirova, Shakhnozakhon, Giudice, Anna M, Martinez, Daniel, Garcia-Gerique, Laura, Dimitrov, Dimiter S, Sondel, Paul M, Bosse, Kristopher R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723962/
https://www.ncbi.nlm.nih.gov/pubmed/36460335
http://dx.doi.org/10.1136/jitc-2022-004704

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723962/
https://www.ncbi.nlm.nih.gov/pubmed/36460335
http://dx.doi.org/10.1136/jitc-2022-004704

Ejemplares similares